LFB key figures

Chiffres Imageheader Resized

Employees who are committed on a daily basis

Image1+Texte Chiffres Resized

♦  2,880 employees in the world in 2023

  • More than 2,200 in France, including 1,600 in production 

♦  More than 300 recruitments planned in 2024

♦  Nearly 50% of parity between women and men in 2023

  • 98/100 gender equality rate in 2023

An international bioproduction

Image2+Texte Chiffres Resized

♦ 5 bioproduction plants in the world, including 4 in France : 

  • Alès (Occitanie region)
  • Arras (Hauts-de-France region )
  • Les Ulis (Ile-de-France region )
  • Lille et Carvin (Hauts-de-France region )

LFB worldwide

Biomedicinal products for serious and often rare diseases

2/3 of LFB biomedicinal products are intended for the treatment of patients with rare diseases 

About fifteen medicines marketed in about 30 countries.

In 3 major therapeutical areas :

  • Immunology,
  • Haemostasis,
  • Intensive Care.

 

Major industrial investments

750 million of euros invested in the new LFB plant in Arras (Hauts-de-France region)

  • Medicinal products capacity multiplied by 3.

20 million of euros invested to double the production capacity at the Alès site (Occitanie region)

  • Manufacturing of monoclonal antibodies multipled by 2.
  • Manufacturing of active substances multiplied by 3.